Integra LifeSciences Showcases ENT Portfolio and Sponsors Clinical Research at AAO-HNSF 2026

  • Integra LifeSciences will showcase its ENT technologies at the AAO-HNSF 2026 Annual Meeting in Los Angeles from October 17-20.
  • The company will highlight products like the ACCLARENT AERA® Eustachian Tube Treatment and RELIEVA SPINPLUS® Balloon Sinuplasty System.
  • Integra is sponsoring new clinical research on chronic ear disease, with a presentation on October 17th by Seilesh C. Babu, M.D.
  • ACCLARENT AERA received FDA clearance for pediatric use in December 2023.

Integra LifeSciences is leveraging the AAO-HNSF 2026 Annual Meeting to reinforce its position in the ENT market, showcasing a range of innovative technologies. The company's sponsorship of clinical research underscores its commitment to advancing evidence-based care, which is crucial in a sector where long-term patient outcomes and regulatory compliance are paramount. The event also serves as a platform to highlight the strategic importance of its FDA-cleared pediatric indication for the ACCLARENT AERA system, potentially opening new market segments.

Clinical Validation
How the outcomes of the Otosclerosis Study Group's research will impact the adoption of Integra's ENT technologies.
Market Expansion
The pace at which Integra can expand the use of ACCLARENT AERA in pediatric patients following FDA clearance.
Competitive Positioning
Whether Integra can sustain its leadership in ENT technologies amid increasing competition.